05/12/2019 09:38:20 |
0 binh luận
Computed tomography features of lung cancer patients before tyrosine kinase inhibitor treatment and response assessment by recist 1.1 SUMMARY Objective: 1. Describe computed tomography features of non-small cell lung cancer before tyrosine kinase inhibitor treatment. 2. Treament response assessment by RECIST 1.1. Patients and metho d: Cross-sectional, retrospective and prospective study of 36 non- small cell lung cancer patients, EGFR mutations positive, treated with Tyrosine Kinase Inhibitor from 08/2018 to 06/2018, having Computed Tomography image after 3 and 6 months treament. Results: Tumors located mainly in peripheral of the lung (77,8%). The most common position is the right upper lobe (30,5%), the least common position is the right middle lobe (5,6%). There are 83,3% of tumors with the size over 3cm. 100% of tumor have irregular and spicules magin. Solid mass accounted for 63,9%, partly solid mass (33,3%), one tumor is cavity form. Medium attenuation value is 27 HU in pre-contrast and 57,1 HU in post-contrast CT scan. Lymph node metastasis in 27 (61%) patients. Lymph node metastasis is mainly occured in paratracheal nodes [2,4(R,L), 3] (48%), A-Pwindow, paraaortic nodes (5,6) (12%), subcarinal nodes (7) (16%), supraclavicular nodes (1) (20%). After 3 months treament, partial response: 17 patients (52,8%), stable disease: 19 patients (47,2%). After 6 months treament, partial response: 14 patients (38,9%), stable disease: 20 patients (55,6%), progressive disease: 2 patients (5,5%). Conclusion: Computed TomographyFeatures can be used to diagnose lung cancer. 2. Tyrosine Kinase Inhibitor Treatment is effective inadvancednonsmall cell lung cancer. Keywords: lung cancer, computed tomography, tyrosine kinase inhibitor treatment, Recist 1.1